401 related articles for article (PubMed ID: 10859303)
1. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL).
Matsumoto M; Sudo T; Saito T; Osada H; Tsujimoto M
J Biol Chem; 2000 Oct; 275(40):31155-61. PubMed ID: 10859303
[TBL] [Abstract][Full Text] [Related]
2. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.
Lee SE; Woo KM; Kim SY; Kim HM; Kwack K; Lee ZH; Kim HH
Bone; 2002 Jan; 30(1):71-7. PubMed ID: 11792567
[TBL] [Abstract][Full Text] [Related]
3. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor.
Matsumoto M; Sudo T; Maruyama M; Osada H; Tsujimoto M
FEBS Lett; 2000 Dec; 486(1):23-8. PubMed ID: 11108836
[TBL] [Abstract][Full Text] [Related]
4. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
5. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
6. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.
Rossa C; Ehmann K; Liu M; Patil C; Kirkwood KL
J Interferon Cytokine Res; 2006 Oct; 26(10):719-29. PubMed ID: 17032166
[TBL] [Abstract][Full Text] [Related]
7. Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand.
Yamamoto A; Miyazaki T; Kadono Y; Takayanagi H; Miura T; Nishina H; Katada T; Wakabayashi K; Oda H; Nakamura K; Tanaka S
J Bone Miner Res; 2002 Apr; 17(4):612-21. PubMed ID: 11918218
[TBL] [Abstract][Full Text] [Related]
8. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.
Zauli G; Rimondi E; Nicolin V; Melloni E; Celeghini C; Secchiero P
Blood; 2004 Oct; 104(7):2044-50. PubMed ID: 15213096
[TBL] [Abstract][Full Text] [Related]
9. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells.
Hotokezaka H; Sakai E; Kanaoka K; Saito K; Matsuo K; Kitaura H; Yoshida N; Nakayama K
J Biol Chem; 2002 Dec; 277(49):47366-72. PubMed ID: 12237315
[TBL] [Abstract][Full Text] [Related]
10. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
11. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
12. Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain.
Kusumi A; Sakaki H; Kusumi T; Oda M; Narita K; Nakagawa H; Kubota K; Satoh H; Kimura H
J Bone Miner Metab; 2005; 23(5):373-81. PubMed ID: 16133687
[TBL] [Abstract][Full Text] [Related]
13. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
14. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
15. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
16. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
Rahman MM; Bhattacharya A; Fernandes G
J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
[TBL] [Abstract][Full Text] [Related]
17. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
Murase Y; Okahashi N; Koseki T; Itoh K; Udagawa N; Hashimoto O; Sugino H; Noguchi T; Nishihara T
J Cell Physiol; 2001 Aug; 188(2):236-42. PubMed ID: 11424090
[TBL] [Abstract][Full Text] [Related]
18. Participation of protein kinase C beta in osteoclast differentiation and function.
Lee SW; Kwak HB; Chung WJ; Cheong H; Kim HH; Lee ZH
Bone; 2003 Mar; 32(3):217-27. PubMed ID: 12667549
[TBL] [Abstract][Full Text] [Related]
19. Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration.
Kwak HB; Lee SW; Jin HM; Ha H; Lee SH; Takeshita S; Tanaka S; Kim HM; Kim HH; Lee ZH
Blood; 2005 Apr; 105(7):2963-9. PubMed ID: 15585657
[TBL] [Abstract][Full Text] [Related]
20. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
